Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Nordic Nanovector ASA (NANO) NOK0.2

Sell:29.20 NOK Buy:29.28 NOK Change: 1.74 NOK (6.34%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
Sell:29.20 NOK
Buy:29.28 NOK
Change: 1.74 NOK (6.34%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
Sell:29.20 NOK
Buy:29.28 NOK
Change: 1.74 NOK (6.34%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nordic Nanovector ASA is a Norway-based company active in the biotechnology industry. It is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). It is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. It has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.

Contact details

Address:
Kjelsasveien 168 B
OSLO
0884
Norway
Telephone:
+47 (2) 2183301
Website:
www.nordicnanovector.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NANO
ISIN:
NO0010597883
Market cap:
1.57 billion NOK
Shares in issue:
57.32 million
Sector:
Biotechnology
Exchange:
Oslo Stock Exchange
Country:
Norway
Currency:
Norwegian Krone
Indices:
Oslo All Share Index

Key personnel

  • Jan Egberts
    Independent Chairman of the Board
  • Eduardo Bravo Fernandez de Araoz
    Chief Executive Officer
  • Tone Kvale
    Chief Financial Officer
  • Marco Renoldi
    Chief Operating Officer
  • Rita Dege
    Chief Human Resources Officer
  • Lars Nieba
    Chief Technology Officer
  • Jostein Dahle
    Chief Scientific Officer
  • Fredrik Haavind
    Head of Legal and Compliance
  • Malene Brondberg
    Vice President Investor Relations and Corporate Communications
  • Gabriele Elbl
    Vice President Global Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.